At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Pilot Study Evaluation of the Efficacy of SonoVue to Detect and Characterise Breast Lesions
In Brief
A clinical study evaluating SonoVue (sulphur hexafluoride microbubbles) for Breast Tumors. Completed, enrolled 59 participants across 1 site.
Detailed Summary
Ultrasound is a well-established imaging modality for the evaluation of breast disease. The investigators' objective is to characterise the properties of an intravascular ultrasonographic contrast agent SonoVue (sulphur hexafluoride microbubbles) to improve the diagnostic value of the ultrasound examination in patients with different breast lesions. The final purpose of this ultrasonography is to allow the early detection of tumors and to improve the differentiation between benign and malignant lesions. SonoVue® (sulphur hexafluoride microbubbles) is a microbubbles preparation that is stable, resistant to pressure, and specifically designed to be used as a contrast agent for ultrasound imaging. Contrast-enhanced ultrasound could provide a non-invasive technique to evaluate the morphology of breast tumour vascularity.
Study Details
Timeline
Interventions
One contrast enhanced ultrasonography using sonovue / 4.8 ml per injection (maximum of 3 injections)